Never too late: Forbion pitches $100M SPAC; Kronos Bio releases early interim data on CDK9 inhibitor
Dutch VC Forbion is hopping on the ever-lengthening SPAC train.
To be led by Jasper Bos, who joined Forbion Growth as a general partner back in May just after the fund closed at $428 million, Forbion European Acquisition will target late-stage opportunities in the life sciences industry in Europe to merge with and bring onto Nasdaq.
Cyril Lesser, senior controller at Forbion, will be the CFO while Bos serves as CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.